{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T15:12:41Z","timestamp":1767971561359,"version":"3.49.0"},"reference-count":97,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2021,1,7]],"date-time":"2021-01-07T00:00:00Z","timestamp":1609977600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2021,1,7]],"date-time":"2021-01-07T00:00:00Z","timestamp":1609977600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Drugs Ther"],"published-print":{"date-parts":[[2021,10]]},"DOI":"10.1007\/s10557-020-07124-4","type":"journal-article","created":{"date-parts":[[2021,1,7]],"date-time":"2021-01-07T11:04:21Z","timestamp":1610017461000},"page":"1045-1056","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":30,"title":["Ivabradine in Cardiovascular Disease Management Revisited: a Review"],"prefix":"10.1007","volume":"35","author":[{"given":"Christopher","family":"Chen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3693-7722","authenticated-orcid":false,"given":"Gurleen","family":"Kaur","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Puja K.","family":"Mehta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Doralisa","family":"Morrone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lucas C.","family":"Godoy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sripal","family":"Bangalore","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mandeep S.","family":"Sidhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,1,7]]},"reference":[{"key":"7124_CR1","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1093\/oxfordjournals.aje.a113046","volume":"112","author":"AR Dyer","year":"1980","unstructured":"Dyer AR, Persky V, Stamler J, et al. Heart rate as a prognostic factor for coronary heart disease and mortality: findings in three Chicago epidemiologic studies. Am J Epidemiol. 1980;112:736\u201349.","journal-title":"Am J Epidemiol"},{"key":"7124_CR2","doi-asserted-by":"publisher","first-page":"1489","DOI":"10.1016\/0002-8703(87)90666-1","volume":"113","author":"WB Kannel","year":"1987","unstructured":"Kannel WB, Kannel C, Paffenbarger RS, Cupples LA. Heart rate and cardiovascular mortality: the Framingham study. Am Heart J. 1987;113:1489\u201394.","journal-title":"Am Heart J"},{"key":"7124_CR3","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1016\/0002-8703(91)90970-S","volume":"121","author":"RF Gillum","year":"1991","unstructured":"Gillum RF, Makuc DM, Feldman JJ. Pulse rate, coronary heart disease, and death: the NHANES I epidemiologic follow-up study. Am Heart J. 1991;121:172\u20137.","journal-title":"Am Heart J"},{"key":"7124_CR4","doi-asserted-by":"publisher","first-page":"1477","DOI":"10.1161\/hc3801.096325","volume":"104","author":"UE Heidland","year":"2001","unstructured":"Heidland UE, Strauer BE. Left ventricular muscle mass and elevated heart rate are associated with coronary plaque disruption. Circulation. 2001;104:1477\u201382.","journal-title":"Circulation."},{"key":"7124_CR5","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/j.amjmed.2014.09.016","volume":"128","author":"M B\u00f6hm","year":"2015","unstructured":"B\u00f6hm M, Reil JC, Deedwania P, Kim JB, Borer JS. Resting heart rate: risk indicator and emerging risk factor in cardiovascular disease. Am J Med. 2015;128:219\u201328.","journal-title":"Am J Med"},{"key":"7124_CR6","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1136\/heartjnl-2012-302301","volume":"99","author":"M B\u00f6hm","year":"2013","unstructured":"B\u00f6hm M, Reil JC. Heart rate: surrogate or target in the management of heart failure? Heart. 2013;99:72\u20135.","journal-title":"Heart."},{"key":"7124_CR7","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1016\/j.jacc.2007.04.079","volume":"50","author":"K Fox","year":"2007","unstructured":"Fox K, Borer JS, Camm AJ, Danchin N, Ferrari R, Lopez Sendon JL, et al. Resting heart rate in cardiovascular disease. J Am Coll Cardiol. 2007;50:823\u201330.","journal-title":"J Am Coll Cardiol"},{"key":"7124_CR8","doi-asserted-by":"publisher","first-page":"2850","DOI":"10.1161\/01.CIR.94.11.2850","volume":"94","author":"H Tsuji","year":"1996","unstructured":"Tsuji H, Larson MG, Venditti FJ Jr, et al. Impact of reduced heart rate variability on risk for cardiac events. The Framingham Heart Study. Circulation. 1996;94:2850\u20135.","journal-title":"Circulation"},{"key":"7124_CR9","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/j.ahj.2011.04.012","volume":"162","author":"G Fragasso","year":"2011","unstructured":"Fragasso G, De Cobelli F, Spoladore R, et al. Resting cardiac energy metabolism is inversely associated with heart rate in healthy young adult men. Am Heart J. 2011;162:136\u201341.","journal-title":"Am Heart J"},{"key":"7124_CR10","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1136\/heartjnl-2017-311275","volume":"104","author":"M Nathania","year":"2018","unstructured":"Nathania M, Hollingsworth KG, Bates M, Eggett C, Trenell MI, Velicki L, et al. Impact of age on the association between cardiac high-energy phosphate metabolism and cardiac power in women. Heart. 2018;104:111\u20138.","journal-title":"Heart."},{"key":"7124_CR11","doi-asserted-by":"publisher","first-page":"1777","DOI":"10.1016\/j.jacc.2017.08.038","volume":"70","author":"JS Koruth","year":"2017","unstructured":"Koruth JS, Lala A, Pinney S, Reddy VY, Dukkipati SR. The clinical use of ivabradine. J Am Coll Cardiol. 2017;70:1777\u201384.","journal-title":"J Am Coll Cardiol"},{"key":"7124_CR12","doi-asserted-by":"publisher","first-page":"e136","DOI":"10.1016\/j.hrthm.2015.09.019","volume":"13","author":"RL Page","year":"2016","unstructured":"Page RL, Joglar JA, Caldwell MA, Calkins H, Conti JB, Deal BJ, et al. 2015 ACC\/AHA\/HRS guideline for the management of adult patients with supraventricular tachycardia: a report of the American College of Cardiology\/American Heart Association task force on clinical practice guidelines and the Heart Rhythm Society. Heart Rhythm. 2016;13:e136\u2013221.","journal-title":"Heart Rhythm"},{"key":"7124_CR13","doi-asserted-by":"publisher","first-page":"2949","DOI":"10.1093\/eurheartj\/eht296","volume":"34","author":"G Montalescot","year":"2013","unstructured":"Montalescot G, Sechtem U, Achenbach S, et al. 2013 ESC guidelines on the management of stable coronary artery disease: the task force on the management of stable coronary artery disease of the European Society of Cardiology. Eur Heart J. 2013;34:2949\u20133003.","journal-title":"Eur Heart J"},{"key":"7124_CR14","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1093\/eurheartj\/ehz425","volume":"41","author":"J Knuuti","year":"2020","unstructured":"Knuuti J, Wijns W, Saraste A, Capodanno D, Barbato E, Funck-Brentano C, et al. 2019 ESC guidelines for the diagnosis and management of chronic coronary syndromes. Eur Heart J. 2020;41:407\u201377.","journal-title":"Eur Heart J"},{"key":"7124_CR15","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1038\/nrd3576","volume":"10","author":"O Postea","year":"2011","unstructured":"Postea O, Biel M. Exploring HCN channels as novel drug targets. Nat Rev Drug Discov. 2011;10:903\u201314.","journal-title":"Nat Rev Drug Discov"},{"key":"7124_CR16","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.pharmthera.2005.01.005","volume":"107","author":"M Baruscotti","year":"2005","unstructured":"Baruscotti M, Bucchi A, Difrancesco D. Physiology and pharmacology of the cardiac pacemaker (\"funny\") current. Pharmacol Ther. 2005;107:59\u201379.","journal-title":"Pharmacol Ther"},{"key":"7124_CR17","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1016\/j.phrs.2006.03.006","volume":"53","author":"D DiFrancesco","year":"2006","unstructured":"DiFrancesco D. Funny channels in the control of cardiac rhythm and mode of action of selective blockers. Pharmacol Res. 2006;53:399\u2013406.","journal-title":"Pharmacol Res"},{"key":"7124_CR18","doi-asserted-by":"publisher","first-page":"1757","DOI":"10.2165\/00003495-200464160-00003","volume":"64","author":"D DiFrancesco","year":"2004","unstructured":"DiFrancesco D, Camm JA. Heart rate lowering by specific and selective I(f) current inhibition with ivabradine. Drugs. 2004;64:1757\u201365.","journal-title":"Drugs."},{"key":"7124_CR19","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1038\/sj.bjp.0706940","volume":"150","author":"C Thollon","year":"2007","unstructured":"Thollon C, Bedut S, Villeneuve N, Cog\u00e9 F, Piffard L, Guillaumin JP, et al. Use-dependent inhibition of hHCN4 by ivabradine and relationship with reduction in pacemaker activity. Br J Pharmacol. 2007;150:37\u201346.","journal-title":"Br J Pharmacol"},{"key":"7124_CR20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1085\/jgp.20028593","volume":"120","author":"A Bucchi","year":"2002","unstructured":"Bucchi A, Baruscotti M, DiFrancesco D. Current-dependent block of rabbit sino-atrial node I(f) channels by ivabradine. J Gen Physiol. 2002;120:1\u201313.","journal-title":"J Gen Physiol"},{"key":"7124_CR21","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1016\/j.ehj.2003.10.010","volume":"25","author":"X Monnet","year":"2004","unstructured":"Monnet X, Colin P, Ghaleh B, Hittinger L, Giudicelli JF, Berdeaux A. Heart rate reduction during exercise-induced myocardial ischaemia and stunning. Eur Heart J. 2004;25:579\u201386.","journal-title":"Eur Heart J"},{"key":"7124_CR22","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1124\/jpet.103.059717","volume":"308","author":"P Colin","year":"2004","unstructured":"Colin P, Ghaleh B, Monnet X, Hittinger L, Berdeaux A. Effect of graded heart rate reduction with ivabradine on myocardial oxygen consumption and diastolic time in exercising dogs. J Pharmacol Exp Ther. 2004;308:236\u201340.","journal-title":"J Pharmacol Exp Ther"},{"key":"7124_CR23","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1159\/000073933","volume":"100","author":"M Manz","year":"2003","unstructured":"Manz M, Reuter M, Lauck G, Omran H, Jung W. A single intravenous dose of ivabradine, a novel If inhibitor, lowers heart rate but does not depress left ventricular function in patients with left ventricular dysfunction. Cardiology. 2003;100:149\u201355.","journal-title":"Cardiology."},{"key":"7124_CR24","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1177\/1060028016631571","volume":"50","author":"ER Weeda","year":"2016","unstructured":"Weeda ER, Nguyen E, White CM. Role of ivabradine in the treatment of patients with cardiovascular disease. Ann Pharmacother. 2016;50:475\u201385.","journal-title":"Ann Pharmacother"},{"key":"7124_CR25","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1056\/NEJMoa1406430","volume":"371","author":"K Fox","year":"2014","unstructured":"Fox K, Ford I, Steg PG, Tardif JC, Tendera M, Ferrari R. Ivabradine in stable coronary artery disease without clinical heart failure. N Engl J Med. 2014;371:1091\u20139.","journal-title":"N Engl J Med"},{"key":"7124_CR26","first-page":"573","volume":"23","author":"L N\u00fa\u00f1ez","year":"2016","unstructured":"N\u00fa\u00f1ez L, Crespo-Leiro MG, Marr\u00f3n-Li\u00f1ares GM, Suarez-Fuentetaja N, Barge-Caballero E, Paniagua-Mart\u00edn MJ, et al. Analysis of variants in the HCN4 gene and in three single nucleotide polymorphisms of the CYP3A4 gene for association with ivabradine reduction in heart rate: a preliminary report. Cardiol J. 2016;23:573\u201382.","journal-title":"Cardiol J"},{"key":"7124_CR27","doi-asserted-by":"publisher","first-page":"poc.5000190","DOI":"10.5301\/poc.5000190","volume":"1","author":"L Di Lullo","year":"2015","unstructured":"Di Lullo L, Bellasi A, Russo D, et al. Ivabradine, heart failure and chronic kidney disease. Nephrol @ Point Care. 2015;1:poc.5000190.","journal-title":"Nephrol @ Point Care"},{"key":"7124_CR28","doi-asserted-by":"publisher","first-page":"2441","DOI":"10.1161\/01.CIR.103.20.2441","volume":"103","author":"TR Wallhaus","year":"2001","unstructured":"Wallhaus TR, Taylor M, DeGrado TR, et al. Myocardial free fatty acid and glucose use after carvedilol treatment in patients with congestive heart failure. Circulation. 2001;103:2441\u20136.","journal-title":"Circulation."},{"key":"7124_CR29","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1111\/j.1472-8206.2012.01029.x","volume":"27","author":"R Spoladore","year":"2013","unstructured":"Spoladore R, Fragasso G, Perseghin G, de Cobelli F, Esposito A, Maranta F, et al. Beneficial effects of beta-blockers on left ventricular function and cellular energy reserve in patients with heart failure. Fundam Clin Pharmacol. 2013;27:455\u201364.","journal-title":"Fundam Clin Pharmacol"},{"key":"7124_CR30","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.pcad.2009.05.004","volume":"52","author":"M Valentini","year":"2009","unstructured":"Valentini M, Parati G. Variables influencing heart rate. Prog Cardiovasc Dis. 2009;52:11\u20139.","journal-title":"Prog Cardiovasc Dis"},{"key":"7124_CR31","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1016\/S0140-6736(10)61198-1","volume":"376","author":"K Swedberg","year":"2010","unstructured":"Swedberg K, Komajda M, B\u00f6hm M, Borer JS, Ford I, Dubost-Brama A, et al. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. Lancet. 2010;376:875\u201385.","journal-title":"Lancet."},{"key":"7124_CR32","doi-asserted-by":"publisher","first-page":"1506","DOI":"10.1136\/heartjnl-2014-305482","volume":"100","author":"RI Martin","year":"2014","unstructured":"Martin RI, Pogoryelova O, Koref MS, et al. Atrial fibrillation associated with ivabradine treatment: meta-analysis of randomised controlled trials. Heart. 2014;100:1506\u201310.","journal-title":"Heart."},{"key":"7124_CR33","doi-asserted-by":"publisher","first-page":"83","DOI":"10.2165\/00126839-200304020-00001","volume":"4","author":"AJ Camm","year":"2003","unstructured":"Camm AJ, Lau C-P. Electrophysiological effects of a single intravenous administration of ivabradine (S 16257) in adult patients with normal baseline electrophysiology. Drugs R D. 2003;4:83\u20139.","journal-title":"Drugs R D"},{"key":"7124_CR34","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1159\/000108387","volume":"108","author":"L L\u00f3pez-Besc\u00f3s","year":"2007","unstructured":"L\u00f3pez-Besc\u00f3s L, Filipova S, Martos R. Long-term safety and efficacy of ivabradine in patients with chronic stable angina. Cardiology. 2007;108:387\u201396.","journal-title":"Cardiology."},{"key":"7124_CR35","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1111\/j.1469-7793.1999.813ab.x","volume":"515","author":"GC Demontis","year":"1999","unstructured":"Demontis GC, Longoni B, Barcaro U, Cervetto L. Properties and functional roles of hyperpolarization-gated currents in guinea-pig retinal rods. J Physiol. 1999;515:813\u201328.","journal-title":"J Physiol"},{"key":"7124_CR36","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.1016\/S0028-3908(99)00207-5","volume":"39","author":"T-O Satoh","year":"2000","unstructured":"Satoh T-O, Yamada M. A bradycardiac agent ZD7288 blocks the hyperpolarization-activated current (Ih) in retinal rod photoreceptors. Neuropharmacology. 2000;39:1284\u201391.","journal-title":"Neuropharmacology."},{"key":"7124_CR37","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1038\/sj.bjp.0706998","volume":"150","author":"L Cervetto","year":"2007","unstructured":"Cervetto L, Demontis GC, Gargini C. Cellular mechanisms underlying the pharmacological induction of phosphenes. Br J Pharmacol. 2007;150:383\u201390.","journal-title":"Br J Pharmacol"},{"key":"7124_CR38","doi-asserted-by":"publisher","first-page":"2001","DOI":"10.1016\/S0140-6736(99)04440-2","volume":"353","author":"MERIT-HF Study Group","year":"1999","unstructured":"MERIT-HF Study Group. Effect of metoprolol CR\/XL in chronic heart failure: metoprolol CR\/XL randomised intervention trial in congestive heart failure (MERIT-HF). Lancet. 1999;353:2001\u20137.","journal-title":"Lancet."},{"key":"7124_CR39","doi-asserted-by":"publisher","first-page":"2194","DOI":"10.1161\/01.CIR.0000035653.72855.BF","volume":"106","author":"M Packer","year":"2002","unstructured":"Packer M, Fowler MB, Roecker EB, Coats AJ, Katus HA, Krum H, et al. Effect of carvedilol on the morbidity of patients with severe chronic heart failure: results of the carvedilol prospective randomized cumulative survival (COPERNICUS) study. Circulation. 2002;106:2194\u20139.","journal-title":"Circulation."},{"key":"7124_CR40","doi-asserted-by":"publisher","first-page":"784","DOI":"10.7326\/0003-4819-150-11-200906020-00006","volume":"150","author":"FA McAlister","year":"2009","unstructured":"McAlister FA, Wiebe N, Ezekowitz JA, Leung AA, Armstrong PW. Meta-analysis: beta-blocker dose, heart rate reduction, and death in patients with heart failure. Ann Intern Med. 2009;150:784\u201394.","journal-title":"Ann Intern Med"},{"key":"7124_CR41","doi-asserted-by":"publisher","first-page":"e137","DOI":"10.1161\/CIR.0000000000000509","volume":"136","author":"CW Yancy","year":"2017","unstructured":"Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE Jr, Colvin MM, et al. 2017 ACC\/AHA\/HFSA focused update of the 2013 ACCF\/AHA guideline for the management of heart failure: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. Circulation. 2017;136:e137\u2013e61.","journal-title":"Circulation."},{"key":"7124_CR42","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1007\/s11886-018-0978-7","volume":"20","author":"B Bozkurt","year":"2018","unstructured":"Bozkurt B. What is new in heart failure management in 2017? Update on ACC\/AHA Heart Failure Guidelines. Curr Cardiol Rep. 2018;20:39.","journal-title":"Curr Cardiol Rep"},{"key":"7124_CR43","doi-asserted-by":"publisher","first-page":"2129","DOI":"10.1093\/eurheartj\/ehw128","volume":"37","author":"P Ponikowski","year":"2016","unstructured":"Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JGF, Coats AJS, et al. 2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2016;37:2129\u2013200.","journal-title":"Eur Heart J"},{"key":"7124_CR44","doi-asserted-by":"publisher","first-page":"2813","DOI":"10.1093\/eurheartj\/ehs259","volume":"33","author":"JS Borer","year":"2012","unstructured":"Borer JS, B\u00f6hm M, Ford I, et al. Effect of ivabradine on recurrent hospitalization for worsening heart failure in patients with chronic systolic heart failure: the SHIFT study. Eur Heart J. 2012;33:2813\u201320.","journal-title":"Eur Heart J"},{"key":"7124_CR45","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1007\/s00392-012-0467-8","volume":"102","author":"M B\u00f6hm","year":"2013","unstructured":"B\u00f6hm M, Borer J, Ford I, Gonzalez-Juanatey JR, Komajda M, Lopez-Sendon J, et al. Heart rate at baseline influences the effect of ivabradine on cardiovascular outcomes in chronic heart failure: analysis from the SHIFT study. Clin Res Cardiol. 2013;102:11\u201322.","journal-title":"Clin Res Cardiol"},{"key":"7124_CR46","doi-asserted-by":"publisher","first-page":"1890","DOI":"10.1016\/j.amjcard.2015.09.029","volume":"116","author":"M B\u00f6hm","year":"2015","unstructured":"B\u00f6hm M, Robertson M, Ford I, Borer JS, Komajda M, Kindermann I, et al. Influence of cardiovascular and noncardiovascular co-morbidities on outcomes and treatment effect of heart rate reduction with Ivabradine in stable heart failure (from the SHIFT trial). Am J Cardiol. 2015;116:1890\u20137.","journal-title":"Am J Cardiol"},{"key":"7124_CR47","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1159\/000380812","volume":"131","author":"EA Bocchi","year":"2015","unstructured":"Bocchi EA, B\u00f6hm M, Borer JS, Ford I, Komajda M, Swedberg K, et al. Effect of combining ivabradine and \u03b2-blockers: focus on the use of carvedilol in the SHIFT population. Cardiology. 2015;131:218\u201324.","journal-title":"Cardiology."},{"key":"7124_CR48","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1093\/eurjhf\/hfs127","volume":"15","author":"M Komajda","year":"2013","unstructured":"Komajda M, B\u00f6hm M, Borer J, Ford I, Krum H, Tase A, et al. Influence of background treatment with mineralocorticoid receptor antagonists on ivabradine's effects in patients with chronic heart failure. Eur J Heart Fail. 2013;15:79\u201384.","journal-title":"Eur J Heart Fail"},{"key":"7124_CR49","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1002\/ejhf.1021","volume":"20","author":"M B\u00f6hm","year":"2018","unstructured":"B\u00f6hm M, Komajda M, Borer JS, Ford I, Maack C, Tavazzi L, et al. Duration of chronic heart failure affects outcomes with preserved effects of heart rate reduction with ivabradine: findings from SHIFT. Eur J Heart Fail. 2018;20:373\u201381.","journal-title":"Eur J Heart Fail"},{"key":"7124_CR50","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1159\/000449243","volume":"136","author":"JS Borer","year":"2017","unstructured":"Borer JS, Swedberg K, Komajda M, Ford I, Tavazzi L, B\u00f6hm M, et al. Efficacy profile of Ivabradine in patients with heart failure plus angina pectoris. Cardiology. 2017;136:138\u201344.","journal-title":"Cardiology."},{"key":"7124_CR51","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1002\/ejhf.114","volume":"16","author":"M Komajda","year":"2014","unstructured":"Komajda M, B\u00f6hm M, Borer JS, Ford I, Robertson M, Manolis AJ, et al. Efficacy and safety of ivabradine in patients with chronic systolic heart failure according to blood pressure level in SHIFT. Eur J Heart Fail. 2014;16:810\u20136.","journal-title":"Eur J Heart Fail"},{"key":"7124_CR52","doi-asserted-by":"publisher","first-page":"2507","DOI":"10.1093\/eurheartj\/ehr311","volume":"32","author":"JC Tardif","year":"2011","unstructured":"Tardif JC, O'Meara E, Komajda M, B\u00f6hm M, Borer JS, Ford I, et al. Effects of selective heart rate reduction with ivabradine on left ventricular remodelling and function: results from the SHIFT echocardiography substudy. Eur Heart J. 2011;32:2507\u201315.","journal-title":"Eur Heart J"},{"key":"7124_CR53","doi-asserted-by":"publisher","first-page":"1977","DOI":"10.1016\/j.jacc.2013.07.027","volume":"62","author":"JC Reil","year":"2013","unstructured":"Reil JC, Tardif JC, Ford I, Lloyd SM, O'Meara E, Komajda M, et al. Selective heart rate reduction with ivabradine unloads the left ventricle in heart failure patients. J Am Coll Cardiol. 2013;62:1977\u201385.","journal-title":"J Am Coll Cardiol"},{"key":"7124_CR54","doi-asserted-by":"publisher","first-page":"2395","DOI":"10.1093\/eurheartj\/ehr343","volume":"32","author":"I Ekman","year":"2011","unstructured":"Ekman I, Chassany O, Komajda M, B\u00f6hm M, Borer JS, Ford I, et al. Heart rate reduction with ivabradine and health related quality of life in patients with chronic heart failure: results from the SHIFT study. Eur Heart J. 2011;32:2395\u2013404.","journal-title":"Eur Heart J"},{"key":"7124_CR55","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1002\/ehf2.12513","volume":"6","author":"N Bouabdallaoui","year":"2019","unstructured":"Bouabdallaoui N, O'Meara E, Bernier V, Komajda M, Swedberg K, Tavazzi L, et al. Beneficial effects of ivabradine in patients with heart failure, low ejection fraction, and heart rate above 77 b.p.m. ESC Heart Fail. 2019;6:1199\u2013207.","journal-title":"ESC Heart Fail"},{"key":"7124_CR56","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1536\/ihj.18-559","volume":"60","author":"H Pei","year":"2019","unstructured":"Pei H, Miao W, Xie WZ, Wang W, Zhao D, Su GH, et al. Ivabradine improves cardiac function and increases exercise capacity in patients with chronic heart failure. Int Heart J. 2019;60:899\u2013909.","journal-title":"Int Heart J"},{"key":"7124_CR57","doi-asserted-by":"publisher","first-page":"1938","DOI":"10.1016\/j.jacc.2012.01.020","volume":"59","author":"K Swedberg","year":"2012","unstructured":"Swedberg K, Komajda M, B\u00f6hm M, Borer J, Robertson M, Tavazzi L, et al. Effects on outcomes of heart rate reduction by ivabradine in patients with congestive heart failure: is there an influence of beta-blocker dose?: findings from the SHIFT (systolic heart failure treatment with the I(f) inhibitor ivabradine trial) study. J Am Coll Cardiol. 2012;59:1938\u201345.","journal-title":"J Am Coll Cardiol"},{"key":"7124_CR58","doi-asserted-by":"publisher","first-page":"2066","DOI":"10.1161\/CIRCULATIONAHA.115.018094","volume":"133","author":"MA Psotka","year":"2016","unstructured":"Psotka MA, Teerlink JR. Ivabradine: role in the chronic heart failure armamentarium. Circulation. 2016;133:2066\u201375.","journal-title":"Circulation."},{"key":"7124_CR59","doi-asserted-by":"publisher","first-page":"1296","DOI":"10.1093\/eurjhf\/hft102","volume":"15","author":"L Tavazzi","year":"2013","unstructured":"Tavazzi L, Swedberg K, Komajda M, B\u00f6hm M, Borer JS, Lainscak M, et al. Efficacy and safety of ivabradine in chronic heart failure across the age spectrum: insights from the SHIFT study. Eur J Heart Fail. 2013;15:1296\u2013303.","journal-title":"Eur J Heart Fail"},{"key":"7124_CR60","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.ijcard.2016.04.136","volume":"217","author":"FJ Hidalgo","year":"2016","unstructured":"Hidalgo FJ, Anguita M, Castillo JC, Rodr\u00edguez S, Pardo L, Dur\u00e1n E, et al. Effect of early treatment with ivabradine combined with beta-blockers versus beta-blockers alone in patients hospitalised with heart failure and reduced left ventricular ejection fraction (ETHIC-AHF): a randomised study. Int J Cardiol. 2016;217:7\u201311.","journal-title":"Int J Cardiol"},{"key":"7124_CR61","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.ahj.2019.12.024","volume":"223","author":"RJ Mentz","year":"2020","unstructured":"Mentz RJ, DeVore AD, Tasissa G, et al. PredischaRge initiation of Ivabradine in the ManagEment of Heart Failure: results of the PRIME-HF trial. Am Heart J. 2020;223:98\u2013105.","journal-title":"Am Heart J"},{"key":"7124_CR62","doi-asserted-by":"publisher","first-page":"1946","DOI":"10.1016\/j.jacc.2012.01.019","volume":"59","author":"M Sarraf","year":"2012","unstructured":"Sarraf M, Francis GS. It is all about heart rate. Or is it? J Am Coll Cardiol. 2012;59:1946\u20137.","journal-title":"J Am Coll Cardiol"},{"key":"7124_CR63","doi-asserted-by":"publisher","first-page":"351","DOI":"10.2459\/JCM.0000000000000661","volume":"19","author":"L Tondi","year":"2018","unstructured":"Tondi L, Fragasso G, Spoladore R, Pinto G, Gemma M, Slavich M, et al. Real-life indications to ivabradine treatment for heart rate optimization in patients with chronic systolic heart failure. J Cardiovasc Med (Hagerstown). 2018;19:351\u20136.","journal-title":"J Cardiovasc Med (Hagerstown)"},{"key":"7124_CR64","doi-asserted-by":"publisher","first-page":"e004112","DOI":"10.1161\/CIRCHEARTFAILURE.117.004112","volume":"10","author":"D Das","year":"2017","unstructured":"Das D, Savarese G, Dahlstr\u00f6m U, Fu M, Howlett J, Ezekowitz JA, et al. Ivabradine in heart failure: the representativeness of SHIFT (Systolic Heart Failure Treatment With the IF Inhibitor Ivabradine Trial) in a broad population of patients with chronic heart failure. Circ Heart Fail. 2017;10:e004112.","journal-title":"Circ Heart Fail"},{"key":"7124_CR65","doi-asserted-by":"publisher","first-page":"1961","DOI":"10.1136\/heartjnl-2011-300041","volume":"97","author":"D Cullington","year":"2011","unstructured":"Cullington D, Goode KM, Cleland JG, Clark AL. Limited role for ivabradine in the treatment of chronic heart failure. Heart. 2011;97:1961\u20136.","journal-title":"Heart."},{"key":"7124_CR66","doi-asserted-by":"publisher","first-page":"1330","DOI":"10.1016\/j.jacc.2013.06.043","volume":"62","author":"W Kosmala","year":"2013","unstructured":"Kosmala W, Holland DJ, Rojek A, Wright L, Przewlocka-Kosmala M, Marwick TH. Effect of if-channel inhibition on hemodynamic status and exercise tolerance in heart failure with preserved ejection fraction: a randomized trial. J Am Coll Cardiol. 2013;62:1330\u20138.","journal-title":"J Am Coll Cardiol"},{"key":"7124_CR67","doi-asserted-by":"publisher","first-page":"1719","DOI":"10.1161\/CIRCULATIONAHA.115.017119","volume":"132","author":"N Pal","year":"2015","unstructured":"Pal N, Sivaswamy N, Mahmod M, Yavari A, Rudd A, Singh S, et al. Effect of selective heart rate slowing in heart failure with preserved ejection fraction. Circulation. 2015;132:1719\u201325.","journal-title":"Circulation."},{"key":"7124_CR68","doi-asserted-by":"publisher","first-page":"1495","DOI":"10.1002\/ejhf.876","volume":"19","author":"M Komajda","year":"2017","unstructured":"Komajda M, Isnard R, Cohen-Solal A, Metra M, Pieske B, Ponikowski P, et al. Effect of ivabradine in patients with heart failure with preserved ejection fraction: the EDIFY randomized placebo-controlled trial. Eur J Heart Fail. 2017;19:1495\u2013503.","journal-title":"Eur J Heart Fail"},{"key":"7124_CR69","first-page":"e7123","volume":"12","author":"M Nadeem","year":"2020","unstructured":"Nadeem M, Hassib M, Aslam HM, Fatima D, Illahi Y. Role of ivabradine in patients with heart failure with preserved ejection fraction. Cureus. 2020;12:e7123.","journal-title":"Cureus."},{"key":"7124_CR70","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1161\/01.CIR.0000048143.25023.87","volume":"107","author":"JS Borer","year":"2003","unstructured":"Borer JS, Fox K, Jaillon P, Lerebours G. Antianginal and antiischemic effects of ivabradine, an I(f) inhibitor, in stable angina: a randomized, double-blind, multicentered, placebo-controlled trial. Circulation. 2003;107:817\u201323.","journal-title":"Circulation."},{"key":"7124_CR71","doi-asserted-by":"publisher","first-page":"2529","DOI":"10.1093\/eurheartj\/ehi586","volume":"26","author":"JC Tardif","year":"2005","unstructured":"Tardif JC, Ford I, Tendera M, Bourassa MG, Fox K. Efficacy of ivabradine, a new selective I(f) inhibitor, compared with atenolol in patients with chronic stable angina. Eur Heart J. 2005;26:2529\u201336.","journal-title":"Eur Heart J"},{"key":"7124_CR72","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1093\/eurheartj\/ehn571","volume":"30","author":"JC Tardif","year":"2009","unstructured":"Tardif JC, Ponikowski P, Kahan T. Efficacy of the I(f) current inhibitor ivabradine in patients with chronic stable angina receiving beta-blocker therapy: a 4-month, randomized, placebo-controlled trial. Eur Heart J. 2009;30:540\u20138.","journal-title":"Eur Heart J"},{"key":"7124_CR73","doi-asserted-by":"publisher","first-page":"393","DOI":"10.2165\/00003495-200767030-00005","volume":"67","author":"W Ruzyllo","year":"2007","unstructured":"Ruzyllo W, Tendera M, Ford I, Fox KM. Antianginal efficacy and safety of ivabradine compared with amlodipine in patients with stable effort angina pectoris: a 3-month randomised, double-blind, multicentre, noninferiority trial. Drugs. 2007;67:393\u2013405.","journal-title":"Drugs."},{"key":"7124_CR74","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1016\/S0140-6736(08)61170-8","volume":"372","author":"K Fox","year":"2008","unstructured":"Fox K, Ford I, Steg PG, Tendera M, Ferrari R. Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial. Lancet. 2008;372:807\u201316.","journal-title":"Lancet."},{"key":"7124_CR75","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1016\/S0140-6736(08)61172-1","volume":"372","author":"JC Reil","year":"2008","unstructured":"Reil JC, B\u00f6hm M. BEAUTIFUL results--the slower, the better? Lancet. 2008;372:779\u201380.","journal-title":"Lancet."},{"key":"7124_CR76","doi-asserted-by":"publisher","first-page":"2337","DOI":"10.1093\/eurheartj\/ehp358","volume":"30","author":"K Fox","year":"2009","unstructured":"Fox K, Ford I, Steg PG, Tendera M, Robertson M, Ferrari R, et al. Relationship between ivabradine treatment and cardiovascular outcomes in patients with stable coronary artery disease and left ventricular systolic dysfunction with limiting angina: a subgroup analysis of the randomized, controlled BEAUTIFUL trial. Eur Heart J. 2009;30:2337\u201345.","journal-title":"Eur Heart J"},{"key":"7124_CR77","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1016\/j.ahj.2013.06.024","volume":"166","author":"K Fox","year":"2013","unstructured":"Fox K, Ford I, Steg PG, et al. Rationale, design, and baseline characteristics of the Study assessInG the morbidity-mortality beNefits of the If inhibitor ivabradine in patients with coronarY artery disease (SIGNIFY trial): a randomized, double-blind, placebo-controlled trial of ivabradine in patients with stable coronary artery disease without clinical heart failure. Am Heart J. 2013;166:654\u201361.e6.","journal-title":"Am Heart J"},{"key":"7124_CR78","doi-asserted-by":"publisher","first-page":"2047","DOI":"10.1093\/eurheartj\/ehv190","volume":"36","author":"JJ McMurray","year":"2015","unstructured":"McMurray JJ. It is BEAUTIFUL we should be concerned about, not SIGNIFY: is ivabradine less effective in ischaemic compared with non-ischaemic LVSD? Eur Heart J. 2015;36:2047\u20139.","journal-title":"Eur Heart J"},{"key":"7124_CR79","doi-asserted-by":"publisher","first-page":"2042","DOI":"10.1093\/eurheartj\/ehv150","volume":"36","author":"R Ferrari","year":"2015","unstructured":"Ferrari R, Fox KM. The role of heart rate may differ according to pathophysiological setting: from SHIFT to SIGNIFY. Eur Heart J. 2015;36:2042\u20136.","journal-title":"Eur Heart J"},{"key":"7124_CR80","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1161\/HYPERTENSIONAHA.116.07250","volume":"67","author":"SF Rimoldi","year":"2016","unstructured":"Rimoldi SF, Messerli FH, Cerny D, Gloekler S, Traupe T, Laurent S, et al. Selective heart rate reduction with ivabradine increases central blood pressure in stable coronary artery disease. Hypertension. 2016;67:1205\u201310.","journal-title":"Hypertension."},{"key":"7124_CR81","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1016\/j.jacc.2016.03.610","volume":"68","author":"FH Messerli","year":"2016","unstructured":"Messerli FH, Rimoldi SF, Bangalore S, Bavishi C, Laurent S. When an increase in central systolic pressure overrides the benefits of heart rate lowering. J Am Coll Cardiol. 2016;68:754\u201362.","journal-title":"J Am Coll Cardiol"},{"key":"7124_CR82","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1186\/s12872-017-0540-3","volume":"17","author":"HG Mengesha","year":"2017","unstructured":"Mengesha HG, Weldearegawi B, Petrucka P, Bekele T, Otieno MG, Hailu A. Effect of ivabradine on cardiovascular outcomes in patients with stable angina: meta-analysis of randomized clinical trials. BMC Cardiovasc Disord. 2017;17:105.","journal-title":"BMC Cardiovasc Disord"},{"key":"7124_CR83","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1016\/j.clinthera.2015.12.018","volume":"38","author":"C Cammarano","year":"2016","unstructured":"Cammarano C, Silva M, Comee M, Donovan JL, Malloy MJ. Meta-analysis of Ivabradine in patients with stable coronary artery disease with and without left ventricular dysfunction. Clin Ther. 2016;38:387\u201395.","journal-title":"Clin Ther"},{"key":"7124_CR84","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1002\/clc.22585","volume":"39","author":"J Zarifis","year":"2016","unstructured":"Zarifis J, Kallistratos M, Katsivas A. Antianginal efficacy of ivabradine\/metoprolol combination in patients with stable angina. Clin Cardiol. 2016;39:697\u2013702.","journal-title":"Clin Cardiol"},{"key":"7124_CR85","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1007\/s12325-018-0681-5","volume":"35","author":"M Glezer","year":"2018","unstructured":"Glezer M, Vasyuk Y, Karpov Y. Efficacy of ivabradine in combination with beta-blockers versus uptitration of beta-blockers in patients with stable angina (CONTROL-2 study). Adv Ther. 2018;35:341\u201352.","journal-title":"Adv Ther"},{"key":"7124_CR86","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1007\/s00392-011-0402-4","volume":"101","author":"K Werdan","year":"2012","unstructured":"Werdan K, Ebelt H, Nuding S, H\u00f6pfner F, Hack G, M\u00fcller-Werdan U. Ivabradine in combination with beta-blocker improves symptoms and quality of life in patients with stable angina pectoris: results from the ADDITIONS study. Clin Res Cardiol. 2012;101:365\u201373.","journal-title":"Clin Res Cardiol"},{"key":"7124_CR87","doi-asserted-by":"publisher","first-page":"1138","DOI":"10.1161\/HYPERTENSIONAHA.115.06091","volume":"66","author":"JG Dillinger","year":"2015","unstructured":"Dillinger JG, Maher V, Vitale C, Henry P, Logeart D, Manzo Silberman S, et al. Impact of Ivabradine on central aortic blood pressure and myocardial perfusion in patients with stable coronary artery disease. Hypertension. 2015;66:1138\u201344.","journal-title":"Hypertension."},{"key":"7124_CR88","doi-asserted-by":"publisher","first-page":"3392","DOI":"10.1093\/eurheartj\/ehv587","volume":"36","author":"GG Camici","year":"2015","unstructured":"Camici GG, Savarese G, Akhmedov A, Luscher TF. Molecular mechanism of endothelial and vascular aging: implications for cardiovascular disease. Eur Heart J. 2015;36:3392\u2013403.","journal-title":"Eur Heart J"},{"key":"7124_CR89","doi-asserted-by":"publisher","first-page":"e41","DOI":"10.1016\/j.hrthm.2015.03.029","volume":"12","author":"RS Sheldon","year":"2015","unstructured":"Sheldon RS, Grubb BP 2nd, Olshansky B, et al. 2015 heart rhythm society expert consensus statement on the diagnosis and treatment of postural tachycardia syndrome, inappropriate sinus tachycardia, and vasovagal syncope. Heart Rhythm. 2015;12:e41\u201363.","journal-title":"Heart Rhythm"},{"key":"7124_CR90","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1016\/j.jacc.2012.06.031","volume":"60","author":"R Cappato","year":"2012","unstructured":"Cappato R, Castelvecchio S, Ricci C, Bianco E, Vitali-Serdoz L, Gnecchi-Ruscone T, et al. Clinical efficacy of ivabradine in patients with inappropriate sinus tachycardia: a prospective, randomized, placebo-controlled, double-blind, crossover evaluation. J Am Coll Cardiol. 2012;60:1323\u20139.","journal-title":"J Am Coll Cardiol"},{"key":"7124_CR91","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1111\/pace.12118","volume":"36","author":"J BENEZET-MAZUECOS","year":"2013","unstructured":"BENEZET-MAZUECOS J, Rubio JM, Farr\u00e9 J, et al. Long-term outcomes of ivabradine in inappropriate sinus tachycardia patients: appropriate efficacy or inappropriate patients. Pacing Clin Electrophysiol. 2013;36:830\u20136.","journal-title":"Pacing Clin Electrophysiol"},{"key":"7124_CR92","doi-asserted-by":"publisher","first-page":"e12709","DOI":"10.1111\/anec.12709","volume":"25","author":"K Kaczmarek","year":"2020","unstructured":"Kaczmarek K, Klingenheben T, Poddebska I, Urbanek I, Wranicz JK, Cygankiewicz I, et al. Baseline intrinsic heart rate and response to ivabradine treatment in patients with inappropriate sinus tachycardia. Ann Noninvasive Electrocardiol. 2020;25:e12709.","journal-title":"Ann Noninvasive Electrocardiol"},{"key":"7124_CR93","doi-asserted-by":"publisher","first-page":"1318","DOI":"10.1016\/j.hrthm.2010.05.034","volume":"7","author":"L Cal\u00f2","year":"2010","unstructured":"Cal\u00f2 L, Rebecchi M, Sette A, Martino A, de Ruvo E, Sciarra L, et al. Efficacy of ivabradine administration in patients affected by inappropriate sinus tachycardia. Heart Rhythm. 2010;7:1318\u201323.","journal-title":"Heart Rhythm"},{"key":"7124_CR94","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1093\/europace\/eus204","volume":"15","author":"P Ptaszynski","year":"2012","unstructured":"Ptaszynski P, Kaczmarek K, Ruta J, Klingenheben T, Wranicz JK. Metoprolol succinate vs. ivabradine in the treatment of inappropriate sinus tachycardia in patients unresponsive to previous pharmacological therapy. Europace. 2012;15:116\u201321.","journal-title":"Europace."},{"key":"7124_CR95","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1177\/1074248413478172","volume":"18","author":"P Ptaszynski","year":"2013","unstructured":"Ptaszynski P, Kaczmarek K, Ruta J, Klingenheben T, Cygankiewicz I, Wranicz JK. Ivabradine in combination with metoprolol succinate in the treatment of inappropriate sinus tachycardia. J Cardiovasc Pharmacol Ther. 2013;18:338\u201344.","journal-title":"J Cardiovasc Pharmacol Ther"},{"key":"7124_CR96","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1016\/j.hrthm.2017.10.004","volume":"15","author":"ST Mathew","year":"2018","unstructured":"Mathew ST, Po SS, Thadani U. Inappropriate sinus tachycardia\u2013symptom and heart rate reduction with ivabradine: a pooled analysis of prospective studies. Heart Rhythm. 2018;15:240\u20137.","journal-title":"Heart Rhythm"},{"key":"7124_CR97","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1007\/s10840-015-0066-5","volume":"46","author":"M Annamaria","year":"2016","unstructured":"Annamaria M, Lupo PP, Foresti S, de Ambroggi G, de Ruvo E, Sciarra L, et al. Treatment of inappropriate sinus tachycardia with ivabradine. J Interv Card Electrophysiol. 2016;46:47\u201353.","journal-title":"J Interv Card Electrophysiol"}],"container-title":["Cardiovascular Drugs and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10557-020-07124-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10557-020-07124-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10557-020-07124-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,10]],"date-time":"2023-02-10T21:16:10Z","timestamp":1676063770000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10557-020-07124-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,7]]},"references-count":97,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2021,10]]}},"alternative-id":["7124"],"URL":"https:\/\/doi.org\/10.1007\/s10557-020-07124-4","relation":{},"ISSN":["0920-3206","1573-7241"],"issn-type":[{"value":"0920-3206","type":"print"},{"value":"1573-7241","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,7]]},"assertion":[{"value":"7 December 2020","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 January 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}}]}}